GLP-1 trends in June 2025 are redefining obesity treatment—but real-world data reveals more than half of patients quit within a year. This article explores why, what’s coming next, and how providers can adapt to a rapidly changing landscape.
Botox patient satisfaction now defines success in modern aesthetic practice. This guide shows new injectors how to capture feedback, build trust, and grow their business.
Semaglutide is effective for weight loss—but nearly 35% of that loss can be lean muscle. The COURAGE trial from Regeneron explores a novel antibody co-therapy that may protect muscle and improve fat loss outcomes, setting a new bar for obesity treatment.
May 2025 brought conclusive evidence that tirzepatide (Zepbound) produces substantially greater weight loss than semaglutide (Wegovy), with SURMOUNT-5 trial participants losing approximately 20% body weight on tirzepatide versus 14% on semaglutide. Beyond superior weight loss efficacy, GLP-1 medications demonstrated expanded therapeutic benefits for liver disease, cardiovascular health, sleep apnea, and even reduced alcohol consumption, transforming how providers should conceptualize these therapies from ‘weight loss drugs’ to comprehensive metabolic and organ-protective agents.
Learn the clinical definition of obesity and its health risks. Understand BMI’s role in diagnosing obesity.
Discover how FDA-approved non-invasive fat elimination and non-surgical body sculpting techniques are offering effective fat reduction.
Talk with a program advisor to discuss your hands-on or online training options for Botox®, Aesthetic Medicine and Medical Weight Management (GLP-1 inhibitors, semaglutide, tirzepatide and more).
The IAPAM has been helping physicians, nurse practitioners and physician assistants make more & work less with AMA PRA CAT 1 CME certification & training in Botox®, Aesthetic Medicine and Medical Weight Management since 2006.
Choose from online or hands-on training today!
